Latest news and press releases about Akebia Therapeutics, Inc. (AKBA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials.
Price
| Price | $0.92 |
| Market Cap | $246M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 9.66 |
| EV / EBITDA | -8.53 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -93.74% |
| Return on Invested Capital | -7.08% |
| Return on Assets | -8.48% |
| Gross Margin | 79.48% |
| Operating Margin | -6.91% |
| Net Margin | -13.54% |
Related companies: CMPX · CRVS · FDMT · GOSS · KALV · OLMA · PRTA
Explore sector: Healthcare · Biotechnology
More sections of AKBA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks